Search

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.93 2.61

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.76

Max

3.93

Pagrindiniai rodikliai

By Trading Economics

Pajamos

8.3M

-18M

Pardavimai

9.6M

10M

P/E

Sektoriaus vid.

22.5

60.549

Pelnas, tenkantis vienai akcijai

-0.1

Pelno marža

-177.89

Darbuotojai

69

EBITDA

9.5M

-18M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+208.88% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-81M

829M

Ankstesnė atidarymo kaina

1.32

Ankstesnė uždarymo kaina

3.93

Naujienos nuotaikos

By Acuity

50%

50%

180 / 342 reitingas Healthcare

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-09 23:56; UTC

Social Media
News

NVIDIA Corp shares are lower in after-market trading amid concerns about its AI sector performance and intensifying competition from other chip manufacturers.

2026-07-09 23:51; UTC

News
Social Media

Meta Platforms Inc. shares advanced in after-market trading following the launch of Muse Spark 1.1, an AI model aimed at enhancing software development capabilities.

2026-07-09 23:51; UTC

Social Media
News

Netflix is exploring strategies to boost subscriber engagement amid declining viewer interest. Shares fell in after-hours trading following these developments.

2026-07-09 23:46; UTC

News

The United States Oil Fund LP is trading lower in after-market hours, reflecting ongoing geopolitical tensions and a flat trajectory since Thursday's close.

2026-07-09 23:36; UTC

News

Starbucks is developing AI tools to save $2 billion, including $400 million in software costs. Shares are higher in after-market trading.

2026-07-09 23:16; UTC

News

Micron Technology expands U.S. investment to $250 billion by 2035, boosting capital expenditures by $50 billion. Shares rise in after-market trading.

2026-07-09 23:06; UTC

Social Media
News

Tesla shares declined in after-market trading following a Hold rating from Citizens' Andrew Boone, who cited caution on the company's AI timeline.

2026-07-09 20:07; UTC

News

BMO Capital initiated coverage on Align Technology with an Outperform rating and a price target of $209, contributing to positive sentiment despite leadership changes.

2026-07-09 20:07; UTC

Correlated Moves
News

The iShares Core U.S. Aggregate Bond ETF is advancing today, supported by a decline in Treasury yields and positive labor market data.

2026-07-09 20:07; UTC

ETF Constituents
Correlated Moves
News
Social Media

SPDR S&P 500 ETF Trust advances amid mixed market sentiment and geopolitical tensions. Initial jobless claims fell to 215,000, supporting positive momentum.

2026-07-09 20:07; UTC

ETF Constituents
Correlated Moves
News
Social Media

The iShares Russell 2000 ETF is gaining amid geopolitical tensions and positive economic indicators, despite earlier fluctuations in the session.

2026-07-09 20:07; UTC

Social Media
News
Correlated Moves
Macro Event

The iShares iBoxx $ Investment Grade Corporate Bond ETF and iShares TIPS Bond ETF are trading higher, supported by falling Treasury yields and improved jobless claims.

2026-07-09 20:07; UTC

News
Social Media

Alphabet Inc. shares are lower amid concerns about its AI competitiveness, as a report suggests Meta may surpass Google in frontier AI capabilities.

2026-07-09 20:07; UTC

Social Media
Correlated Moves
News

Western Digital shares rise as Micron plans $250 billion investment in U.S. memory production, boosting demand and pricing in the memory chip sector.

2026-07-09 20:07; UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials shares advanced on analyst target increases amid strong demand outlook. The Nasdaq 100's rise also supported the stock's performance.

2026-07-09 20:07; UTC

Social Media
News
Correlated Moves

Broadcom Inc gains as it joins Morningstar's "Cheap Stocks to Buy" list and announces a multiyear, $30 billion partnership with Apple for chip production.

2026-07-09 20:07; UTC

Correlated Moves
Social Media
News

Citibank's CIO survey shows Microsoft leads AI funding, with 69% from new budgets. Shares are trading higher amid positive sentiment and ongoing challenges.

2026-07-09 20:07; UTC

News
Correlated Moves

Ethereum sees $70 million in ETF inflows, the largest in 28 days. Despite negative social media sentiment, the asset is trading higher since Wednesday's close.

2026-07-09 20:07; UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's policy review may also support investor confidence in the cryptocurrency.

2026-07-09 20:07; UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's review of monetary policy may also boost investor confidence.

2026-07-09 20:07; UTC

News
Correlated Moves

Ethereum sees significant inflows of $70 million from ETFs, marking the largest daily increase in 28 days, contributing to its higher trading position since Wednesday.

2026-07-09 20:06; UTC

News

J B Hunt Transport Services is higher today after Goldman Sachs and Citigroup raised their price targets, reflecting positive assessments of the company's performance.

2026-07-09 20:06; UTC

News

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims related to the company's financial practices.

2026-07-09 20:06; UTC

Social Media
News

Shares of Alphabet Inc. are lower amid concerns over its AI competitiveness, following a report suggesting Meta may surpass Google in frontier AI capabilities.

2026-07-09 20:06; UTC

Event
News
Social Media
Correlated Moves

Intuit Inc. shares rise as the company goes ex-dividend for $1.20. Investor interest grows amid overall market strength and positive sentiment in technology stocks.

2026-07-09 20:06; UTC

News
Correlated Moves

Geopolitical tensions following U.S. airstrikes on Iran have increased demand for safe-haven currencies, with CHF/HKD trading slightly higher during Thursday's session.

2026-07-09 20:03; UTC

News
Social Media
Event
Macro Event

PepsiCo Inc's stock is lower following mixed second-quarter earnings, with revenue at $24.18 billion but adjusted EPS of $2.20 missing estimates.

2026-07-09 20:02; UTC

News

Cisco Systems is trading higher as investors respond to its focus on smart building technology, including a partnership showing significant energy efficiency gains.

2026-07-09 20:02; UTC

Social Media
ETF Constituents
News

Invesco QQQ Trust trades higher, recovering above $713.75, as SpaceX's Nasdaq-100 inclusion boosts interest. Strong performances from Meta, Broadcom, and AMD support the ETF.

2026-07-09 20:02; UTC

Macro Event
News
Social Media
Correlated Moves

KLA shares advance as TD Cowen raises price target to $260. Positive sentiment in the semiconductor sector supports the upward movement amid increased AI demand.

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

208.88% į viršų

12 mėnesių prognozė

Vidutinis 11.83 USD  208.88%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

180 / 342 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat